Nasal vs Encapsulated Delivery
Research Comparison

Research Overview

This page compares two delivery formats studied for research peptides and small molecules. The intranasal format is a reconstituted aqueous solution. A metered spray delivers it onto the nasal mucosa. The encapsulated format is a solid powder or lyophilizate. It is filled into capsules or compressed into tablets, often with an enteric coat.

This is a comparison of routes and product forms, not of two molecules. So classical small-molecule identity fields do not apply to the page subject itself. These fields include molecular formula and molecular weight. The identity numbers cited below belong to representative excipients, not to a single active.

The two formats differ in mechanism at the absorption barrier, not at a shared molecular target. The intranasal format is studied as a way to deposit a compound on richly vascularized respiratory epithelium. Reported absorption there bypasses gastrointestinal proteolysis and hepatic first-pass metabolism. A distinguishing feature examined preclinically is the nose-to-brain pathway. The encapsulated format is studied as a way to carry a larger absolute mass in solid form. It must contend with gastric acid and with gastrointestinal and pancreatic proteases. It also faces poor epithelial permeability and first-pass metabolism. Enteric coating plus intestinal permeation enhancers typically address these hurdles.

All statements here describe in-vitro and preclinical research context, plus published human delivery-science literature on the formats themselves. Nothing on this page describes a use, benefit, or outcome for any person. For any specific vialed or encapsulated product, confirm the fill mass and concentration against the batch COA. Confirm the excipient list and purity the same way.

Reference Data

Identity values come from public chemistry databases and vendor documentation. Confirm the exact salt form, molecular weight and purity of a given batch against its Certificate of Analysis (COA).

Structure and Class

Neither format is a single chemical. So the reference identity below describes the format class, not one molecule. It also covers the representative excipients most often studied in each format. The intranasal format is best described as a delivery route (intranasal mucosal delivery). The encapsulated format is best described as a solid oral form (capsule or enteric-coated tablet). In both formats, the peptide active typically begins as a lyophilized powder. The nasal format requires reconstitution to an aqueous spray. The encapsulated format is filled or compressed as a solid.

Representative nasal-format excipients with their own confirmed identity include benzalkonium chloride (PubChem CID 3014024). It is a preservative found in some nasal vehicles. They also include solubilizers such as 2-hydroxypropyl-beta-cyclodextrin (PubChem CID 14049689, molecular formula C63H112O42, molecular weight about 1541.5, reported). Cell-penetrating peptides and mucoadhesive polymers are also studied as nasal absorption modifiers.

Representative encapsulated-format excipients are the intestinal permeation enhancers. Salcaprozate sodium is known as SNAC (PubChem CID 23669833, molecular formula C15H20NNaO4, molecular weight about 301.31, reported). It is the enhancer worked out for oral semaglutide. Sodium caprate is the C10 enhancer (PubChem CID 4457968, molecular formula C10H19NaO2, molecular weight about 194.25, reported). It is the other most clinically advanced enhancer. These two have been studied head-to-head for over thirty years (Twarog 2019, PMID 30781867).

Research Context

Intranasal research context. The intranasal format deposits a compound on nasal respiratory and olfactory mucosa. From there, reported absorption crosses richly vascularized epithelium. That absorption bypasses gastrointestinal proteolysis and hepatic first-pass metabolism. The most distinctive feature studied preclinically is the nose-to-brain (NBDD) pathway. Research indicates direct transport toward the central nervous system. It runs along olfactory and trigeminal nerve routes, plus a respiratory pathway.

This transport reportedly bypasses the blood-brain barrier. It moves by bulk flow and diffusion in perineuronal, perivascular and lymphatic channels. In animal models, some tracers reached brain tissue within roughly ten minutes (Qiu 2025, PMID 40487748). A worked preclinical example comes from a rat Parkinson model (Aly 2015, PMID 26289676). It used intranasal GDNF and plasmid-DNA nanoparticle gene delivery. The approach was a non-surgical alternative to intracerebral infusion.

Mucociliary clearance and enzymatic degradation in nasal mucosa are dominant reported limiters of nasal peptide absorption. A molecular-size cutoff is another dominant limiter. The mucus layer is reported to renew roughly every ten to twenty minutes. This sweeps unabsorbed material to the nasopharynx, where it is swallowed. Peptides under about 1000 Da are reported to absorb reasonably.

Peptides of 1000 to 6000 Da reportedly absorb increasingly poorly. Most marketed intranasal peptide formulations show reported human bioavailability under about 5 percent. The nasal format is also volume-limited. Metered spray typically delivers about 50 to 140 microliters per actuation. An often-cited optimum is roughly 100 microliters per nostril. So only relatively potent, low-mass payloads fit.

Encapsulated research context. The encapsulated format must first survive gastric acid. It must also survive stomach, intestinal and pancreatic proteases. Then it must cross the intestinal epithelium, where large hydrophilic peptides diffuse poorly. Then it must survive hepatic first-pass metabolism. So naked oral peptide bioavailability is characteristically very low. Research formats address this with enteric coating, which shields against acid and pepsin. They also use intestinal permeation enhancers. The canonical enhancer mechanism, worked out for oral semaglutide, is SNAC.

SNAC is reported to buffer the local microenvironment. This raises pH to roughly 5 or above, which inactivates pepsin. SNAC is also reported to reduce peptide oligomerization in favor of the absorbable monomer. Finally, it is reported to briefly and reversibly fluidize the epithelial lipid membrane. This reportedly boosts transcellular passage. Sodium caprate (C10) is reported to work more by transient tight-junction opening plus membrane perturbation (Twarog 2019, PMID 30781867).

The encapsulated permeation-enhancer route is the format with the strongest human validation. It is the delivery basis of oral semaglutide, which was evaluated in large Phase 3 human trials. One is NCT04707469, which compared oral semaglutide 25 or 50 mg versus 14 mg in type 2 diabetes. That program is a research proof-of-concept that a permeation-enhancer capsule can make a peptide orally absorbable. Per the Twarog review, both SNAC and C10 produce single-digit increases in oral bioavailability in human trials. Those increases are reported to be highly variable. By contrast, nasal CNS peptide delivery is largely preclinical to early clinical.

Which Should a Study Use?

Neither format is superior in the abstract. The right choice depends on the payload and the research question. The intranasal format fits a study of a small, potent peptide. It also fits a study of central nervous system exposure via nose-to-brain routes. Such a study accepts the format's volume ceiling and mucociliary clearance losses.

It also accepts the reconstitution and aqueous-stability burden. The encapsulated permeation-enhancer format fits a study of a larger-mass payload. It also fits a study that prioritizes a solid form with an established human proof-of-concept for oral macromolecule absorption. Such a study accepts the acid, protease and first-pass gauntlet. It also accepts a typically single-digit, variable absorbed fraction.

Molecular size is often the deciding variable. The reported nasal thresholds are about 1000 Da (reasonable) and 1000 to 6000 Da (harder). Where a payload sits against them depends on its exact sequence. Confirm this against the batch COA. Whether a specific compound actually crosses the nose-to-brain barrier at a meaningful level is molecule-dependent. It is not established for arbitrary peptides. The cited nose-to-brain evidence is preclinical and tracer-based. Absolute human bioavailability by either route is molecule-specific. This page does not define it.

Practical handling differs sharply between the formats. It should factor into study design. The nasal format introduces daily reconstitution and an aqueous-aggregation risk. The encapsulated format avoids those. But it is sensitive to moisture, heat and any damage to the enteric or enhancer matrix. See the handling section below. Confirm every product-specific value against the batch COA.

Handling Considerations by Format

Shared starting material. Research peptides typically ship as a lyophilized powder. Unreconstituted lyophilized peptide is reported stable for roughly 24 months or more at -20 C. Confirm the exact stability, fill mass and purity of any given vial or capsule against the batch COA.

Nasal format (requires reconstitution). Add the diluent (bacteriostatic or sterile water) slowly down the inside wall of the vial. Never add it directly onto the powder cake. Never add it with force, because shear promotes aggregation. Do not vortex or shake vigorously. Foaming at the air-liquid interface is reported to drive denaturation and irreversible aggregation.

Improper technique is reported to reduce effective concentration by roughly 20 to 30 percent. The reconstituted solution is the least stable state. Reported potency loss is roughly 5 to 8 percent after 2 to 3 hours at 20 to 25 C. It is roughly 20 to 30 percent after 24 hours at room temperature.

General research handling guidance cited: use within about 30 days if reconstituted with bacteriostatic water. With sterile water only, the cited window is about 7 days. Both assume the solution is kept refrigerated. The nasal-specific loss factors to control at use are spray volume and mucociliary clearance.

Metered spray volume is about 50 to 140 microliters per actuation. The target is about 100 microliters per nostril. Mucociliary clearance turns the mucus over about every 10 to 20 minutes. There is also a reported trade-off by deposition site. Anterior deposition gives longer residence but lower permeability. Posterior deposition gives higher permeability but faster clearance.

Encapsulated format (solid, generally no reconstitution). The main handling risks are moisture and heat. So keep capsules and tablets dry, cool and sealed with desiccant. Enteric coats are designed to hold in gastric pH and dissolve in the intestine. Anything that degrades the coat (humidity, mechanical damage) can expose the peptide to gastric proteolysis. Permeation-enhancer tablets depend on a high local enhancer concentration at the mucosa.

So splitting or crushing an enteric or enhancer-matrix tablet can defeat both protection and absorption. All specific storage temperatures, in-use dating and diluent choice are product-specific. So are excipient lists and purity. Confirm each one against the batch COA. For general lyophilized handling and reconstitution math, see the Lyophilized Storage Guide and the Reconstitution Calculator.

More research comparisons

• BPC-157 vs TB-500
• CJC-1295 DAC vs No DAC
• CJC-1295 vs Ipamorelin
• GHK-Cu vs AHK-Cu
• MOTS-c vs 5-Amino-1MQ
• Semax vs Selank